Author

Mireia Pelegrín

Centre National de la Recherche ScientifiqueORCID 0000-0002-0117-2010Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Mar Naranjo‐GómeziD· 2 shared Camille Chatelain· 1 shared Geneviève GarciniD· 1 shared Jan Tavernier· 1 shared Jean‐François FonteneauiD· 1 shared Joëlle S. NaderiD· 1 shared Lucas TrepsiD· 1 shared Manon Souchard· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Mar Naranjo‐GómezORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential Effects of Distinct Type I Interferons and IFN Inducers on Fc Receptor landscape and myeloid cell function

Remi Bru, Océane Paris, Stéphanie Boireau, Mar Naranjo‐Gómez, Mireia Pelegrín

This study examines how different type I interferons and IFN inducers affect Fc receptor expression and function in myeloid cells, revealing cell-type- and stimulus-specific modulation patterns.

bioRxiv · Oct 7, 2026 · PreprintImmunology

A novel tumor-targeted interferon-α/-β receptor 1 antagonist increases replication of oncolytic vesicular stomatitis virus in a mouse mesothelioma model

Thomas Teja Ogor, Yann Bordat, Manon Souchard, Joëlle S. Nader, Geneviève Garcin, Camille Chatelain, Virginie Dehame, Sophie Deshayes, Lucas Treps, Mar Naranjo‐Gómez, Nicolas Boisgerault, Jan Tavernier, Mireia Pelegrín, Jean‐François Fonteneau

This paper develops IFNAR1 antagonists that selectively block IFNAR signaling in tumor cells, enhancing VSV oncolytic activity in mesothelioma and melanoma models.

bioRxiv · Jun 3, 2026 · PreprintImmunology